Hypothesis

Age‑dependent loss of striatal D2 receptors and DAT expression is caused not by nuclear gene dysregulation but by accumulating mtDNA heteroplasmid lesions in midbrain dopamine neurons that trigger a retrograde innate immune signal.

Rationale

• Dopaminergic decline correlates with mitochondrial dysfunction in substantia nigra and VTA, yet no study has directly measured mtDNA mutation load versus D2/DAT trajectories {1}.
• Mitochondrial‑nuclear crosstalk pathways (Parkin‑Ret, Parkin‑PGC‑1α) are essential for mitochondrial integrity in these neurons, and their perturbation mirrors neurodegenerative disease {3,4}.
• DAT loss shows regional vulnerability (dorsal > ventral SN) that could mirror differential mtDNA deletion accumulation {5}.
• Complex I deficiency and mtDNA‑encoded OXPHOS failure impair dopaminergic function, providing a mechanistic bridge from mtDNA damage to neuronal phenotype {6}.

Mechanistic Insight

We propose that specific mtDNA heteroplasmies (e.g., deletions in MT‑ND4 or point mutations in MT‑CYB) increase mitochondrial ROS and release of mtDNA fragments into the cytosol of dopamine neurons. These fragments activate the cytosolic DNA sensor cGAS, leading to STING‑dependent type I IFN production. The resulting paracrine signal engages microglial IFN‑α/β receptors, prompting release of TNF‑α and IL‑1β. Cytokine‑activated NF‑κB in dopamine neurons suppresses transcription of DRD2 and SLC6A3 (DAT) via promoter histone deacetylation, while simultaneously promoting receptor internalization through ERK‑mediated phosphorylation. Thus, mtDNA damage drives both transcriptional downregulation and post‑translational removal of D2 receptors and DAT.

Experimental Plan

1. Measure mtDNA heteroplasmy vs. receptor levels

• Isolate laser‑captured dopamine neurons from young (3 mo) and aged (24 mo) mouse SNc and VTA.
• Quantify heteroplasmy load for common aging mtDNA deletions (e.g., 4977 bp) using duplex qPCR.
• Correlate heteroplasmy percentage with D2 receptor density ([^3H]raclopride binding) and DAT density ([^3H]WIN‑35,428 binding) in the same samples.
• Falsification: No significant correlation across individuals refutes the hypothesis.

2. Causality test via allotopic expression

• Use AAV‑PHP.eB to deliver allotopic, mitochondrially targeted copies of MT‑ND4 (or MT‑CYB) under a TH‑promoter to SNc dopamine neurons of 18‑mo mice.
• Control groups receive AAV‑GFP or allotopic mutant lacking the mitochondrial targeting sequence.
• After 8 weeks, assess heteroplasmy reduction (by qPCR), D2/DAT binding, and locomotor response to amphetamine.
• Prediction: Allotopic rescue lowers heteroplasmy, restores D2/DAT levels, and normalizes reward‑related behavior.
• Falsification: Rescue fails to improve receptor levels despite heteroplasmy reduction, indicating mtDNA is not the driver.

3. Block cGAS‑STING signaling

• Treat aged mice with the STING inhibitor H‑151 or microglia‑specific CSF1R inhibitor PLX5622 for 4 weeks.
• Measure cytokine levels (IFN‑β, TNF‑α) in SNc tissue, D2/DAT binding, and phosphorylated NF‑κB in TH‑positive neurons.
• Prediction: Signaling inhibition reduces neuroinflammation, increases D2/DAT expression without altering mtDNA heteroplasmy.
• Falsification: No change in receptor levels despite pathway blockade, suggesting alternative downstream effectors.

Expected Outcomes and Impact

If heteroplasmy load predicts receptor loss and allotopic expression or STING inhibition rescues D2/DAT phenotypes, the field must shift from nuclear‑centric descriptors to direct mtDNA repair strategies in dopaminergic aging. This would validate mitochondrial DNA as a primary driver, not a passive bystander, and justify targeting mtDNA heterogeneity (e.g., via mitochondrially targeted base editors or allotopic expression) as a therapeutic avenue for age‑related motivational deficits.